Vivanza Biosciences FY26 Net Loss ₹96.54 Lakhs Standalone

Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting a standalone net loss of ₹96.54 lakhs for the year.
Noted resignations of Non-Executive Director Hemant Amrish Parikh (effective March 17, 2026) and Company Secretary & Compliance Officer Chaitra Arora (effective April 30, 2026).
Reconstituted key Board committees including Audit, Nomination & Remuneration, and Stakeholders Relationship Committee effective May 7, 2026.
Statutory auditors Shivam Soni & Co. issued unqualified audit reports for both standalone and consolidated financial results.